行情

NERV

NERV

Minerva
NASDAQ

实时行情|Nasdaq Last Sale

8.11
0.00
0.00%
已收盘, 16:00 09/17 EDT
开盘
8.09
昨收
8.11
最高
8.18
最低
7.97
成交量
27.91万
成交额
--
52周最高
12.95
52周最低
4.070
市值
3.16亿
市盈率(TTM)
-5.8969
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NERV 新闻

  • 德意志银行:年底标普500将大跌13%至2600点
  • 新浪财经综合.3小时前
  • 欧洲8月份汽车销量大幅下滑 行业困境加剧
  • 新浪财经综合.3小时前
  • “脸书”新设独立监督委员会 可否决扎克伯格意见
  • 中国新闻网.3小时前
  • 德国8月纯电动汽车销量同比飙升逾一倍
  • 新浪财经综合.4小时前

更多

所属板块

生物技术和医学研究
+0.26%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

NERV 简况

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.
展开

Webull提供Minerva Neurosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。